Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Doctors warned of NeutroSpec use on patients with cardiopulmonary problems

This article was originally published in Clinica

Executive Summary

Two patients have died of cardiopulmonary failure within half an hour of receiving an injection of NeutroSpec, a radiopharmaceutical imaging agent developed by Palatin Technologies for the diagnosis of equivocal appendicitis. The deaths, as well as other reports of severe reactions following administration of the agent, have led the Cranbury, New Jersey firm and its NeutroSpec marketing partner Mallinkrodt Imaging to alert doctors on the use of NeutroSpec in patients with underlying cardiopulmonary problems.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel